10-K: Milestone Scientific Amends Executive Employment Agreement and Files Annual Report

Milestone Scientific modifies an executive's employment agreement regarding termination benefits and releases its annual report detailing financial performance and operational updates.

Summary

• Milestone Scientific amended an employment agreement with Arjan Haverhals, the CEO, modifying severance terms related to termination without cause or resignation for good reason.
• The amendment includes continued base compensation for two years, car payments for six months, and health benefits for six months, along with accelerated vesting of bonus options.
• The company's annual report for 2023 shows a net loss of $6.9 million, compared to $8.7 million in 2022.
• Product sales increased to $9.8 million in 2023 from $8.8 million in 2022, driven by the launch of an e-commerce platform.
• The company's gross profit increased to $6.8 million in 2023 from $4.9 million in 2022.
• Operating expenses were $13.9 million in 2023, slightly up from $13.7 million in 2022.
• The company has 17 full-time employees and relies on third-party manufacturers for its products.
• Milestone Scientific holds approximately 245 U.S. and foreign patents and 36 registered trademarks.
• The company's cash and cash equivalents and marketable securities were approximately $6.0 million as of December 31, 2023.
• The company is actively pursuing positive cash flows through increased revenue and reduced operating expenses.

Sentiment

Score: 6

Explanation: The document shows some positive trends, such as increased revenue and reduced losses, but also highlights ongoing risks and challenges, such as reliance on third-party manufacturers and the need for additional funding. The sentiment is cautiously optimistic.

Positives

• The company's net loss decreased by approximately $1.8 million year-over-year.
• Gross profit increased by approximately $1.9 million year-over-year.
• The launch of the e-commerce platform has significantly boosted sales.
• The company has a strong intellectual property portfolio with numerous patents and trademarks.
• The company has a reasonable cash position to support operations for the next 12 months.

Negatives

• The company continues to operate at a loss, with a net loss of $6.9 million in 2023.
• The company relies on third-party manufacturers, which poses a risk to supply chain.
• International sales decreased by approximately $724,000 year-over-year.
• The company terminated its agreement with its major U.S. distributor, Henry Schein, as of December 31, 2022.
• The company has a history of operating losses and may need additional funding.

Risks

• The company's reliance on third-party manufacturers exposes it to supply chain disruptions and pricing changes.
• The company's success depends on the market acceptance of its CompuFlo Epidural System.
• The company faces competition from other medical device companies.
• The company's international sales are subject to fluctuations in foreign currency exchange rates and political instability.
• The company may need to raise additional capital, which could dilute existing stockholders.
• The company is exposed to risks associated with the economic, environmental, and political conditions in China.
• The company is subject to substantial domestic and international government regulation.

Future Outlook

The company is focused on expanding its global footprint, establishing its technology as the standard of care, and transitioning to a commercially focused medical device company. They are also pursuing positive cash flows through increased revenue and reduced operating expenses.

Management Comments

• Management believes the company's current cash and liquidity is sufficient to finance operating requirements for at least the next 12 months.
• Management is actively pursuing positive cash flows through increased revenue and reduced operating expenses.

Industry Context

The medical device industry is highly competitive and subject to rapid technological change. Milestone Scientific competes with both established players and new entrants, requiring continuous innovation and effective distribution strategies. The company's focus on computer-controlled injection technology positions it in a niche market with potential for growth.

Comparison to Industry Standards

• Milestone Scientific's reliance on third-party manufacturers is common in the medical device industry, but it also introduces supply chain risks.
• The company's net loss is not uncommon for early-stage medical device companies, but it highlights the need for revenue growth and cost management.
• The company's gross profit margin improvement is a positive sign, indicating better pricing and cost control.
• The launch of an e-commerce platform is a strategic move to increase direct sales and improve margins, similar to other companies adopting direct-to-consumer models.
• The company's intellectual property portfolio is a key asset, providing a competitive advantage against other companies in the market.

Corporate Governance

Legal Proceedings

• Milestone Scientific is not involved in any material litigation.

Related Party Transactions

• Milestone Scientific has a supply agreement with United Systems, whose controlling shareholder is a significant stockholder of Milestone Scientific.
• The company had sales to Milestone China or agents of Milestone China, an entity in which the company formerly had an ownership interest.
• K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with Milestone Scientific to provide financial and business strategic services.
• The company has a royalty agreement with its Director of Clinical Affairs.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital.
• Employees are subject to the company's code of ethics and insider trading policy.
• Customers may benefit from the company's e-commerce platform and new products.
• Suppliers are subject to the company's supply chain risks.
• Creditors are subject to the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to expand its global footprint.
• The company will continue to establish its technology as the standard of care.
• The company will continue to transition to a commercially focused medical device company.
• The company will continue to pursue positive cash flows through increased revenue and reduced operating expenses.

Key Dates

Keywords

Milestone Scientific, employment agreement, annual report, financial results, medical devices, dental products, CompuFlo, e-commerce, patents, trademarks, severance, operating loss, revenue, gross profit, third-party manufacturing